GILD241206P85000
- 0.03
- 0.000.00%
Gilead Sciences Newsroom
Oppenheimer Maintains Gilead Sciences(GILD.US) With Buy Rating, Raises Target Price to $115
Analysts Offer Insights on Healthcare Companies: Xenon (XENE), Legend Biotech (LEGN) and Gilead Sciences (GILD)
Bernstein Maintains Gilead Sciences(GILD.US) With Buy Rating, Maintains Target Price $105
Gilead Sciences Receives 'Buy' Rating Amid Strong HIV Market Position and Promising Future Prospects
Piper Sandler Maintains Gilead Sciences(GILD.US) With Buy Rating, Maintains Target Price $105
RBC Capital Sticks to Their Hold Rating for Gilead Sciences (GILD)
Gilead Sciences Price Target Raised to $96.00/Share From $70.00 by UBS
UBS Initiates Gilead Sciences(GILD.US) With Hold Rating, Announces Target Price $96
Gilead Sciences Is Maintained at Outperform by Mizuho
Gilead Sciences Analyst Ratings
Mizuho Securities Maintains Gilead Sciences(GILD.US) With Buy Rating, Announces Target Price $100
Mizuho Securities Adjusts Price Target on Gilead Sciences to $100 From $90
Argus Research Maintains Gilead Sciences(GILD.US) With Buy Rating, Raises Target Price to $100
Daiwa Securities Adjusts Gilead Sciences Price Target to $90 From $73
Gilead Sciences Is Maintained at Sector Perform by RBC Capital
Gilead Sciences Analyst Ratings
Gilead Sciences Initiated at Outperform by Wolfe Research
Wolfe Research Maintains Gilead Sciences(GILD.US) With Buy Rating, Raises Target Price to $110
TD Cowen Maintains Gilead Sciences(GILD.US) With Buy Rating, Maintains Target Price $95
Gilead Sciences Analyst Ratings